ArticleHuman gene therapy. Clinical development2014

Feasibility and safety of systemic rAAV9-hNAGLU delivery for treating mucopolysaccharidosis IIIB: toxicology, biodistribution, and immunological assessments in primates.

Darren A Murrey et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.